Cybin Inc., operating commercially as Helus Pharma, announced the appointment of Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board. Donohue previously served as Chief Human Resources Officer at Intra-Cellular Therapies, where she scaled the organization through commercialization before its acquisition by Johnson & Johnson in April 2025. Dr. Durgam brings over two decades of CNS drug development experience, having served as Executive Vice President and Chief Medical Officer at Intra-Cellular and played a pivotal role in securing FDA approvals for CAPLYTA. These appointments support Helus Pharma’s growth and preparation for potential commercialization of its proprietary serotonergic agonists pipeline, including HLP003 and HLP004. The company operates in the pharmaceutical industry, developing novel treatments for mental health conditions.

Cybin Inc., doing business as Helus Pharma, filed interim financial statements for the three months ended June 30, 2026. The company reported a net loss of $47.8 million and cash reserves of $166.4 million. During the quarter, Helus Pharma completed an underwritten offering of 10,309,280 common shares at $4.85 per share, generating approximately $46.5 million in net proceeds. The company also announced that enrollment for its pivotal Phase 3 APPROACH trial of HLP003 was completed with 223 participants on July 21, 2026. Helus Pharma operates as a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions.

Cybin Inc. announced the appointment of Michael Halstead as Chief Executive Officer, effective August 3, 2026. Halstead previously served as President of Intra-Cellular Therapies, where he led the company's US$14.6 billion acquisition by Johnson & Johnson in 2025 and managed its commercialization efforts. His appointment coincides with Helus Pharma preparing for topline data readout from the APPROACH Phase 3 study of HLP003 for Major Depressive Disorder, expected in Q4 2026. The company continues enrollment in the EMBRACE Phase 3 study and the EXTEND long-term extension trial. Cybin Inc. operates as a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions.

Helus Pharma (Nasdaq: HELP) announced the completion of enrollment for its APPROACH Phase 3 pivotal study of HLP003 in patients with Major Depressive Disorder (MDD). The study, which enrolled 223 participants, is on track to release topline data in the fourth quarter of 2026. Helus Pharma is a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions.